Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001127602-24-029965
Filing Date
2024-12-23
Accepted
2024-12-23 16:11:24
Documents
1
Period of Report
2024-12-19

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form4.html 4  
1 PRIMARY DOCUMENT form4.xml 4 7184
  Complete submission text file 0001127602-24-029965.txt   8657
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703
Business Address
Doyle Anthony (Reporting) CIK: 0001808688 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-23186 | Film No.: 241573728